The Alopecia drugs in development market research report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Alopecia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Alopecia and features dormant and discontinued products.

GlobalData tracks 125 drugs in development for Alopecia by 106 companies/universities/institutes. The top development phase for Alopecia is preclinical with 52 drugs in that stage. The Alopecia pipeline has 121 drugs in development by companies and four by universities/ institutes. Some of the companies in the Alopecia pipeline products market are: Epibiotech, VeraDermics and Amplifica Holdings Group.

The key targets in the Alopecia pipeline products market include Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC, Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR), and Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

The key mechanisms of action in the Alopecia pipeline product include Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC Inhibitor with nine drugs in Pre-Registration. The Alopecia pipeline products include 12 routes of administration with the top ROA being Topical and 14 key molecule types in the Alopecia pipeline products market including Small Molecule, and Monoclonal Antibody.

Alopecia overview

Alopecia is the partial or complete loss of hair, especially on the scalp; it can occur in patches, on the entire head, or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, exposure to irritants or toxins, burns, injuries, and infections.

For a complete picture of Alopecia’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.